# DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award

Source: https://welltoldgrants.com/grants/w81xwh-21-prarp-adra-dod-peer-reviewed-alzheimers-accelerating-diagnostics/  
Official notice: https://www.grants.gov/search-results-detail/332710

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $15.0 million in total. Applications closed on July 21, 2021.

| Field | Value |
|---|---|
| Opportunity number | W81XWH-21-PRARP-ADRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | July 21, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $15.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD. The FY21 PRARP ADRA encourages applications to consider fluid-based, imaging-based, retinal, or wearable devices as potential diagnostics. Applications must provide a plan that demonstrates access to a suitable cohort and a plan for participant accrual. Suitable cohorts must be relevant to the military risk factor identified as part of the application. Due to nature of the FY21 PRARP ADRA, studies are required to prospectively recruit study participants. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP ADRA applications must be impact-based.

## Questions people ask

### Is W81XWH-21-PRARP-ADRA still open?

No. It closed on July 21, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award?

Closed July 21, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $15.0 million in total for one award.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.